Inactive Instrument

Highlights Tetraphase Pharmaceuticals, Inc.

Equities

US88165N2045

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Tetraphase Pharmaceuticals, Inc. Enters into A Termination of Lease and Voluntary Surrender of Premises Agreement	20-12-18	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-13	CI
La Jolla Pharmaceutical Completes Merger with Tetraphase Pharmaceuticals	20-07-31	CI
La Jolla Pharmaceutical Company completed the acquisition of Tetraphase Pharmaceuticals, Inc..	20-07-27	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-23	CI
United States Food and Drug Administration Approves XERAVA of Tetraphase Pharmaceuticals, Inc	20-06-05	CI
AcelRx Pharmaceuticals, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-03	CI
Tetraphase Pharmaceuticals : ANNOUNCES SECOND AMENDMENT TO MERGER AGREEMENT WITH ACELRX PHARMACEUTICALS FOR INCREASED CONSIDERATION	20-06-01	AQ
Tetraphase Pharmaceuticals : Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration	20-05-29	BU
Tetraphase Pharmaceuticals : AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase	20-05-29	PR
Tetraphase Pharmaceuticals : AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase	20-05-27	PR
Tetraphase Pharmaceuticals : Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration	20-05-27	BU
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	20-05-14	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
La Jolla Pharmaceutical Company made a non-binding proposal to acquire Tetraphase Pharmaceuticals, Inc. for $14.6 million.	20-05-05	CI
Tetraphase Pharmaceuticals : and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement	20-03-16	BU
AcelRx Pharmaceuticals, Inc. definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. for $10.4 million.	20-03-15	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-12	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Tetraphase Pharmaceuticals to Present XERAVA (Eravacycline) Data at IDWeek 2019	19-09-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tetraphase Pharmaceuticals, Inc.

Equities

US88165N2045

Highlights

Filters